MarketPulse

chronic spontaneous urticaria

7 articles
BenzingaBenzinga··Vandana Singh

Sanofi Beats Earnings as Dupixent Expansion Into Pediatric Urticaria Broadens Growth

Sanofi's Dupixent gains FDA approval for pediatric urticaria as Q1 earnings beat expectations with 30.8% drug growth at $12.31B sales.
SNYREGNchronic spontaneous urticariaFDA approval
GlobeNewswire Inc.GlobeNewswire Inc.··Sanofi And Regeneron

Sanofi and Regeneron Win FDA Nod for Dupixent in Young Children With Chronic Urticaria

FDA approves Dupixent for children ages 2-11 with chronic spontaneous urticaria, marking first biologic treatment for this pediatric population.
SNYREGNchronic spontaneous urticariaFDA approval
GlobeNewswire Inc.GlobeNewswire Inc.··Sanofi And Regeneron

Dupixent Wins FDA Nod for Young Children With Chronic Urticaria, Expanding Market Reach

FDA approves Dupixent for children ages 2-11 with uncontrolled chronic spontaneous urticaria, marking first biologic treatment for this pediatric population.
SNYREGNchronic spontaneous urticariaFDA approval
GlobeNewswire Inc.GlobeNewswire Inc.··Sanofi And Regeneron

Sanofi, Regeneron Win EU Nod for Dupixent in Young Children with Chronic Urticaria

Dupixent gains European approval for treating moderate-to-severe chronic spontaneous urticaria in children ages 2-11, expanding the drug's pediatric portfolio.
SNYREGNchronic spontaneous urticariaDupixent
GlobeNewswire Inc.GlobeNewswire Inc.··Novartis

Novartis Showcases Dermatology Pipeline Momentum With Early-Relief Data at AAD 2026

Novartis presents 20+ abstracts at AAD 2026, highlighting rapid symptom relief with Rhapsido and long-term efficacy data for Cosentyx across multiple skin conditions.
NVSchronic spontaneous urticariaimmunology
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Septerna's SEP-631 Shows Promise in Mast Cell Disease Treatment

Septerna reports positive Phase 1 data for SEP-631, an experimental oral treatment for mast cell-driven diseases, with plans for Phase 2b development beginning late 2026.
SEPNchronic spontaneous urticariaoral small-molecule
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Celldex Touts Sustained Efficacy Data for Mast Cell Antibody Barzolvolimab

Celldex's mast cell antibody barzolvolimab showed strong Phase 2 efficacy for urticaria, with 71% of patients achieving complete response. Phase 3 data expected Q4 2026.
CLDXbarzolvolimabchronic spontaneous urticaria